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Abstract 
An effecuve vaccme for acqUJred mmune deficiency syndrome (AIDS) 
has eluded researchers since the identification of the HIV virus. There 
are many challenges in developing an effective HIV vaccine, includ· 
ing the lack ot knowledge regarding the immune response to the virus 
and its diverse nature. Ethical concerns further complicate research. 
A recent phase Ill trial was perlormed in Thailand and showed that a 
sigrnficant reductK>n m HIV infection 1s possible. Pharmacists need to 
stay informed of these important breakthroughs in AIDS research in or-
der to provide quality health information to patients in their community 
This paper auns to evaluate the pist failures and successes as welt as 
explore the recent advancements towards finding a vaccine for HIV. 
An esumated 33.4 m11ton 1nd1viduals worldwide are currently hving 
with acquired immune deficiency syndrome (AIDS).' According to the 
Centers for Disease Control and Prevention, approximately 56,300 
new cases of Human lrnmunodetciency Virus (HIV) developed dunng 
2006 in the United States alone.2 A cure tor this disease has puzzled 
and eluded rasearchers smce the 1dentihcalron of the HIV virus rn 1983. 
However, hope IS on the honzon wrtb the advances m research that 
could eventually lead to an effective HIV· 1 vaccine. As one of the most 
accessible heahh care providers, pharmacists need to stay informed on 
these 1mµJrtant breakthroughs in HIVJAIDS research in order to provide 
quality heahh infonnation to patients in their community. 
Background 
Although there is currently no cure for HIV, there are several effective antt-
retroviral tmarrnems available. Commencement of therapy is recommended 
for all palienlS with a c04· count <350 cellstmm3 or in patienlS with an AIDS-
defin1ng illness (PneumocysllS pneUTionia, Kaposi sarcoma, cryptococcostS, 
etc.}. Goals of therapy currently include suppressing plasma HIV viral load, 
redoc1ng HIV·assoctated morbidity and mortality, improving quality of fife, 
restonng and i:xeserving immunologic function, and preventing HIV uans-
mission. The De~ent for Health and Human Services (DHHS) Panel 
recommends several preferred and alternative complex multklrug regimens 
HIV/AIDS Prevention-Vaccine Research Timeline: 
rorHIV-positive patients. Treatment should be tndivldualtZed 00.sed on 
virologic efficacy, toxicity, pill burden, dosing frequeocy, drug-<1rug interaction 
potential, msistance testing msults and co-morbid condiOOns. 3 Despite great 
improvements m disease management for HIV/AIDS, the "first-fine therapy" 
is avoidance ot infection in the first place. This has prompted interest in the 
devalopment of an HIV vaccine. 
The biggest challenge in developing an eff9ctive HIV vaccine is that 
the immune response to the HIV infection is not fully understood. Re-
search is further complicated because the virus is exrremely diverse and 
consrantly changing. A successful vaccine would need to be effecuve 
agamsr multiple forms of the virus. In many developing countries, the 
most common strain of the virus 1s w1ld·type or non-mutated; whereas in 
the U.S., med1cat1on-resistant HIV strains are of important concern. Wrth 
a nse In the prevalence of HIV-2 and HIV· 112 viral strains 1n the United 
States. development of successful vaccination formulat10ns becomes 
even more difficult. Another obstacle m the development of a vaccme 
IS the fact that people with HIV cannot hght off the virus. and mounting 
an immune response to a vaccine 1s necessary to prevent or reduce 
infection. Other ma p r challenges include the inabihty to use attenuated 
viruses in humans, absence of a small animal model, and relanvely little 
pharmaceutical interest 4 Although it seems there are many impossible 
rarriers to overcome, learning from the previous mistakes and success-
ful outcomes of prior research have already Jed to significant advances 
toward development of a successful vaccine. 
Testing methods 
HIV is an ever-elusive, ever-changing virus. It IS imp>rtam that the tech-
niques and assays used m AIDS vaccine research improve as the virus 
changes. Canarypox is the vector of chotee 1n developing a vaccine. It 1s 
an anenuared virus that can carry a large quantty or foreign genes and 
enter into human calls yet cannot grow or replicate wrthm them. lnrerferon·y 
enzyme-finked 1mmunospot assays, or ELI Spot assays, are newer assay 
technologies that allow detection of certain secreted cytokmes at a single 
cell level. a ualttanve enzyme-linked immunosol'OOnt assays. or ELI SAs, 
1980 1981 1982 19113 1984 1985 1!186 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 20()4 2005 2006 2007 
I 
1981: Be91nnrng 
of the HIV/AIDS 
epdemic. 
1987 FDA 
authorizes first 
hurran testing 
of vaccine 
aga1ns1 HIV.' 
I 
1997 President Clinton l'.J!)poses 
goal of finding a vaccine in 10 years • 
1998: First phase Ill clinical 
I rials for HIV vaccine l:eg1n. • 
1999: Firs1 human tnals rn a developing 
country (Thailand) fora vaCClne begin. s 
2000: Millennium Vaccine frntralrve creates 
incentives for developing vaccines for HIV.• 
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2003: AIDSVAX 
tnal, first large 
phase Ill human 
lnal of an HIV 
vaccine. Results 
report no protec· 
t!On against 
HIV.• 
I I I 
2007: STEP (HVTN 502/MERCK 023) and PHAM· 
BILI (HVTN 503} piase llb lnals hahed because 
data showed no ooneld and potential increase 
in risk for HIV infection. The vaccine, MRK ·Ad5, 
combined synthetic fragrrenls ol HIV wnh an adeno· 
virus-oosed vector, expec1ed to produce a strong 
immune response. Phase I and II tnals showed 
promising rates of rmmunogenic responses. 
2007: A phase II study ol an HIV· 1 canarypox 
vaccine (vCP 1452) is JXJblished in lhe Journal of 
.Acquired Immune Deficiency Syndromes.• 
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are used to determine how many arnbodies are in a certain sample or how 
much protein IS bound to the antibodies. Chromium release assays are also 
frequently i:xirtormed. ThlS IS accomplished by incuooting infected cells 1n 
chromium, and then, as the cells die by COS· CTL induced apoptostS, the 
chromium IS released from the cell and can be measured as an rnd1cator of 
effecbve immune response. These various methods of data analyses are 
ulililed i11 ma11y curre11t AIDS vaccire studil:ls a11d am U1l:l 111eU10ds or ctl()i!..'e 
in the followrng three tnal summaries. 
Clinical trials 
A phase Ill, community-based, randomized, multicenter, double-blind, 
placebo-controlled trial was performed in Thailand to assess the efficacy 
of four priming in)'lctions of a recombinant canarypox vector vaccine 
and two booster in,actJons of a recombinant glycoprotein 120 subunit 
vaccine. A total of 16,395 healthy men and women were recrrnted for 
the study. Participants were monitored for HIV infection at the end of the 
six-month vaccination senes and then every six months thereafter for 
three years. Adverse reactions to the vaccines were mild ro moderate. 
The vaccine group had a statistically significant lower infection rate com-
pared to placebo {efficacy 31.2%, p < 0.04 ). The study had an extremely 
large sample size and a long duration: however, it lacked correcoon for 
possible lifestyle, disease state or ge net1c differences. This tnal showed 
that a statistically sigrnficant reduction in HIV infection ls possible. 
Further studies must be i:xirformed to examine the individual parameters 
that could have led to such results.11 
A double-blind. randomized, phase II trial was performed to assess 
the efficacy of HIV-1 canarypox v~ccine candidate vCP1452 alone or 
in combination with rgp120 subunit protein. Healthy HIV-1-uninfected 
adults were recruited to participate. The vCP1452 alone was admin-
istered in the left arm to 120 participants, and protein rpg120 was ad-
ministered in combination with vCP1452 to 120 participants in the right 
arm. The remaming 90 participants received placebo. Overall, vCP1452 
and rpg 120 were well tolerated. A significant immune mob1hzat1on could 
not be found in any of the four treatment groups with the vanous assay 
methods. This study was Che first large, multicenter trial to test cell 
secretion via the ELI Spot assay metllOd. It was performed to determine 
if vCP 1452 had a COS· CTL 1nduct1on frequency of at least 30 i:xircent. 
since this 1nducti0n rate was not reached, plans for future vCP1452 trials 
were abandoned.' 
FWJre Timeline: 
2008 2009 2010 2011 2012 
l r 1 1 
2008 A~set 
study involving 
cross-sullyJX! 
ant11:xxJies ard 
su00equent cellular 
immune res~nses 
indu:ed 1:1,t a ~ly­
valent DNA HIV-1 
vaccme (DP6-00I 
formufat10n) is pub-
lished in VaCCtne." 
2009: ALV/JC-AIDSVAX (RV 144) ~se Ill tnal 
completed, with mrtial data showing a 31 JX!rcent 
risk redix:tt0n in oocoming infected with HIV when 
1reated with a pnme-lxlost vaocme comblnatron 
vs. placebo. No eltect was oooerved on viral load. 
Data analyslS IS still ongoing.' 
2009 The Thailand tnal, which studied the efficacy 
of four pnm1ng miections of a recombinant canary-
pox vector vaccine and two lx>oster 1nject1ons of 
a recombinant glycoprote1n 120 subunn vaccine, 
A phase I clinical trial was conducted on HIV-1-specific immune 
responses rn healthy adult volunteers that received the mult:J-gene, 
polyvalent, DNA prime-protein boost HIV-1 vaccine tormulat1on DP6-
oo 1. HIV-1-negative adult volunteers or both genders were randomly as-
signed to either Group A or 8, and once these participants had received 
the second protein boost and a safety review was conducted, enrollment 
111 Gruuµ C was wrnµletl:ld. Tl1l:lrl:l were a tola of 27 volumeers. G1oups 
A and B were administered 1.2 mg of DNA and at each vaccination 
site, and group C was given a much higher dose of7.2 mg. Serum and 
PBMC samples were collected periodically throughout the study to mea-
sure antibody and cell-mediated immune (CMI) rasponses. Participants 
did not exhibit any serious adverse effects. Group C also demonstrated 
a higher CMI response than Groups A and Band still showed fairly high 
levels at the end of the trial (p<0.05). Analyses showed that the antibod-
ies were widely cross-reactive against a range of HIV-1 Env ant:lgens 
and were able to neutralize pseudotyped viruses that expressed the 
primary Env antigens from several HIV-1 subtyf:X!S. Unfortunately, the 
trial experienced reactogenicity in Group C causing investigators to rer-
mrnate the study early in that group. Overall, !!le data demonstrated that 
the ONA pnme-protein boost lmmumzat1on method rs an effective way to 
generate humoral and CMI responses in humans. Moreover, the results 
showed that a polyvalent Env formulation could produce extensive 1m-
munogenrcity against a wide range of HIV-1 v1ruses. 10 
Discussion 
The Thailand trial was a critical breakthrough ooint in HIV/AIDS research 
because vaccine efficacy against the HIV virus has been established 
for the first time. Despite abandonment of the vCP1452 trial, it was still 
of importance because it was the first to utilize new assay techniques. 
According to researchers in the study using the OPS-001 vaccine, further 
studies need to be conducted to assess the structural basis for antibody 
and CMI cross reactivities. The arrangement of Env antigens should 
be enhanced in order to increase the srrength of neutralrzing acuvities 
against resistant viruses. Finally, before progressing ro more m-depth 
human srud1es, the immunization schedule with adJUvant medicatt0n 
regimen needs to be improved to reduce 1mmunogenic1ty of the DP6-
001 formulation. Future trials should focus on determining the body's 
defense mechanisms against the HIV virus, this would allow tor more 
specifrc vaccine targeting in order to improve immune system response. 
2010: CDC 4370~ Phase II/Ill study forthe safety andelfrcacy of daily teoofovir-diso-
pnxrl fumarate (TDF) as pre-ex~sure prophylaxis to prevent HIV infection an'Klng 
inject10n drug wers. 
CDC 4940 Phase Ill trial for the safety and effrcacy o1daily1erolovir-Orsoproxil 
lumarate and emtncitabine (TOFiFTC) as pre-exµ:isure JX0phylax1S to prevent HIV 
1nfec1ron arrong heterosexual sexually active young adults.' 
2011: 1Pr£x Phase Ill trial of daily TOF/FTC as pre-exµ:isure pophylaxlS to preveni 
HIV infection arrong homosexual sexually active men' 
2012: HVTN 505 Randomized, placebo-controlled ptase 11 tnal evaluating sa fely 
and efficacy of multiclade HIV· t DNA plasmid vaccine followed 1:1,t rnulticlade HIV -1 
recomtxnam adeoovirat vector vaccine (prime-00os1strategy)1n redix:lllg viral load of 
trose wt-o l:econ-e infected with HIV after receiving the vaccire c:onbnat10n.' 
IS pobhshed in Deceml:er in the New England 
Journal of Medicine.• May2010 Volume one. Issue one THE P HARMACY AND W aLNess Review 21 
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While there IS an obvious role for an HIV vaccine, there are many 
ethical concerns regarding the chrical efficacy testing. For some popula-
uons, vaccine adm1msrrauon may actually put ind1v1duals at a greater 
risk for developing the disease and/or may cause them to expenence 
more rapid progress10n of the disease once infected, this was one of the 
reasons for halting Merck's clinical trial 1n 2007. 11 Another ma pr ethlC3.I 
c::uncern 1:; tllal sludy µailicipanl\; may l1av~ fals~ exµictaLiuns upon 
receiving the vaccine. For instance, if trial participants believe they have 
developed immunity to the HIV virus resulting from vaccine administra-
tion, they may choose to participate in behaviors that could put them at a 
greater risk for developing HIV (illegal drug use, sexual practices, etc. ). 
Fortunately, evidence has ind cated that subjects in previous trials 
have not engaged in behavioral disinhibition. 12 Most of these studies 
also take place in undeveloped countries , where the need for an HIV 
vaccine ts greatest However. because scientific and financial resources 
for the development of these vaccines come from developed countnes, 
there ts apprehension that the trials may not be conducted under strin-
gent ethical and scientific standards. It is extremely important that all trial 
participants are educated about the risks associated with receiving the 
vaccine and informed that no vaccine has yet been clmJCally effective. If 
any of these issues are not addressed before tnal m1tia!lon, the ethical 
conduction of the tnal must be questioned. 11 
Due to the fact that trials of a traditional model of vaccine have pro-
duced mixed results, some researchers have turned to more novel ap-
proaches in creating an HIV vaccine. For example, the Aaron Diamond 
AIDS Research Center has begun research with ibalizumab, a mono-
clonal antibody that can block viral entry into the CD4• cell. Rather than 
boosting the immune system and preparing the body to fight infection 
like traditional vaccines, an ibalizumab vaccine would provide the body 
with all the defenses necessary to fight the infection. 13 
Conclusion 
New and mnovaove ideas, comb1red with the knowledge from previous 
research, are vital to the growth and development of a successful vac-
cine for HIV. Despite the many obstacles, advances have been made, 
providing hope that someday HIV will no longer have the power to infect 
a staggenng 56,300 American lives and millions more around the world 
each year. 
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